Novel SARS-CoV-2/COVID-19: Origin, pathogenesis, genes and genetic variations, immune responses and phylogenetic analysis
| Autor: | Saif ur Rehman, Musarrat Abbas Khan, Rozhgar A. Khailany, Muhamad Safdar, Yasmeen Junejo, Mehmet Ozaslan, Wasim Yousaf |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty TGEV transmissible gastroenteritis virus Evolution Pathogenesis Biology medicine.disease_cause Variations SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 Article WHO World Health Organization 03 medical and health sciences Origin 0302 clinical medicine Immune system Genetic variation Pandemic medicine Genetics ACE2 angiotensin receptor 2 Gene Coronavirus Phylogenetic analysis IBV avian infectious bronchitis viruses Phylogenetic tree SARS-CoV-2 BCoV bovine coronavirus Public health 030104 developmental biology COVID-19 Coronavirus Disease 2019 030220 oncology & carcinogenesis |
| Zdroj: | Gene Reports |
| ISSN: | 2452-0144 |
| DOI: | 10.1016/j.genrep.2020.100752 |
| Popis: | In this review, we focused on the origins of the novel coronavirus (SARS-CoV-2), origin, pathogenesis, immune responses, genes and genetic variations, phylogenetic analyses, and potential therapeutic strategies to summarize approaches for developing broadly effective preventions and vaccines to cope COVID-19. Towards the end of 2019, SARS-CoV-2 has emerged in association with the SARS, later was named COVID-19 caused an environment of chaos worldwide and infected a massive number of lives. Since these epidemics or pandemics had spread to 210 countries and territories around the world and 2 international conveyances with 6,467,229 confirmed cases, including, 382,766 deaths, as of June 03, 2020 (https://www.worldometers.info/coronavirus/), hence the World Health Organization declared it as a global Public Health Emergency. There are no clinically approved vaccines or antiviral drugs available for either of new or old corona infections; thus, the development of effective therapeutic and preventive strategies that can be readily available to cope with these strains. Highlights • The re-emergence of SARS-CoV-2 as pandemic situation. • SARS-CoV-2 adopted different genomic levels of genetic variations. • Clinically SARS-CoV-2 can cause mild to severe respiratory tract infection and activate antibody-dependent enhancement. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect